DDInter645 DDInter1628
Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies. Enoxaparin markedly reduces the incidence of venous thromboembolism in hospitalized patients when compared to unfractionated [heparin], without increasing the risk of serious bleeding.[A228178,A228313]
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012. In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in steroid-refractory acute graft-versus-host disease in adults and children. The topical formulation of ruxolitinib is used to treat atopic dermatitis and vitiligo. It is being investigated for other inflammatory skin conditions. Ruxolitinib has been investigated to treat patients with coronavirus disease 2019 (COVID-19) accompanied by severe systemic hyperinflammation. In phase II clinical trials, ruxolitinib improved chest computed tomography and improved recovery in patients with lymphopenia.[A229713, A229718] However, phase III clinical trials later determined that ruxolitinib was inadequate in meeting its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe complications thus the drug was not approved as a treatment for COVID-19.
Enoxaparin {u} (Compound) causes {v} (Side Effect) Anaemia
Anaemia {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Enoxaparin {u} (Compound) binds {v} (Gene) SERPINC1
SERPINC1 {u} (Gene) regulates {v} (Gene) AKAP8L
AKAP8L {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Enoxaparin {u} (Compound) binds {v} (Gene) MPO
MPO {u} (Gene) is downregulated by {v} (Disease) and {u} (Disease) associated with {v} (Gene) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Ruxolitinib
Enoxaparin {u} (Compound) binds {v} (Gene) F10
F10 {u} (Gene) regulates {v} (Gene) POLE2
POLE2 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Enoxaparin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Citalopram
Citalopram {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Enoxaparin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pentosan polysulfate
Pentosan polysulfate {u} (Compound) causes {v} (Side Effect) Haematuria
Haematuria {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Enoxaparin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Citalopram
Citalopram {u} (Compound) upregulates {v} (Gene) RRS1
RRS1 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Enoxaparin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Citalopram
Citalopram {u} (Compound) downregulates {v} (Gene) TSPAN4
TSPAN4 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Enoxaparin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Icosapent
Icosapent {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Enoxaparin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Desvenlafaxine
Desvenlafaxine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Enoxaparin (Compound) causes Anaemia (Side Effect) and Anaemia (Side Effect) is caused by Ruxolitinib (Compound)
Enoxaparin (Compound) binds SERPINC1 (Gene) and SERPINC1 (Gene) regulates AKAP8L (Gene) and AKAP8L (Gene) is upregulated by Ruxolitinib (Compound)
Enoxaparin (Compound) binds MPO (Gene) and MPO (Gene) is downregulated by hematologic cancer (Disease) and MPO (Disease) associated with hematologic cancer (Gene) and hematologic cancer (Disease) is treated by Ruxolitinib (Compound)
Enoxaparin (Compound) binds F10 (Gene) and F10 (Gene) regulates POLE2 (Gene) and POLE2 (Gene) is downregulated by Ruxolitinib (Compound)
Enoxaparin may cause a moderate interaction that could exacerbate diseases when taken with Citalopram and Citalopram (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Enoxaparin may cause a moderate interaction that could exacerbate diseases when taken with Pentosan polysulfate and Pentosan polysulfate (Compound) causes Haematuria (Side Effect) and Haematuria (Side Effect) is caused by Ruxolitinib (Compound)
Enoxaparin may cause a moderate interaction that could exacerbate diseases when taken with Citalopram and Citalopram (Compound) upregulates RRS1 (Gene) and RRS1 (Gene) is upregulated by Ruxolitinib (Compound)
Enoxaparin may cause a moderate interaction that could exacerbate diseases when taken with Citalopram and Citalopram (Compound) downregulates TSPAN4 (Gene) and TSPAN4 (Gene) is downregulated by Ruxolitinib (Compound)
Enoxaparin may cause a moderate interaction that could exacerbate diseases when taken with Icosapent and Icosapent (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Ruxolitinib (Compound)
Enoxaparin may cause a moderate interaction that could exacerbate diseases when taken with Desvenlafaxine and Desvenlafaxine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)